WASHINGTON — It’s the eve of a major speech by the president, and it’s anyone’s guess what he will say about drug pricing. Swirling rumors have roiled the pharmaceutical industry and Congress over the past week. Top leaders in Congress have no idea what the White House actually supports. Sound familiar?
Democratic leaders in the White House and Congress clearly aren’t on the same page, a division reminiscent of the yearslong infighting over drug pricing policy under Republican leadership in Washington — an infighting Democrats often criticized. It’s a noticeable contrast from the trillions of dollars worth of domestic policy President Biden’s team has released in his first 100 days in office, which has come out with remarkable discipline and near-uniform support from the rest of the party.